Treatment of oral lichen planus with topical pimecrolimus 1% cream [2]

British Journal of Dermatology

Volumn 150, Issue 4, 2004, Pages 771-773

  Esquivel Pedraza, L ^a   Fernandez Cuevas L ^b,c   Ortiz Pedroza G ^a   Reyes Gutierrez E ^a   Orozco Topete, R ^a  

^a Inst Natl Cie Medicas Nutr S   (Mexico)

^b Universidad Intercontinental   (Mexico)

^c National University of Mexico   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; ANTIFUNGAL AGENT; AZATHIOPRINE; CLOBETASOL PROPIONATE; DERMATOLOGICAL AGENT; MOMETASONE FUROATE; PIMECROLIMUS;

ADULT; AGED; ANAMNESIS; ANTIMICROBIAL THERAPY; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; CREAM; FEMALE; FOLLOW UP; HUMAN; HYPERKERATOSIS; LABORATORY TEST; LETTER; LICHEN PLANUS; MALE; OINTMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN BIOPSY; SKIN INFILTRATE; TREATMENT INDICATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LICHEN PLANUS, ORAL; MALE; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 19244365312     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0007-0963.2004.05875.x     Document Type: Letter

References (7)

1. Axéll T. Oral lichen planus - demographic study. Community Dent Oral Epidemiol 1987; 15: 52-6.
2. Eisen D. The clinical manifestations and treatment of oral lichen planus. Dermatol Clin 2003; 21: 79-89.
3. Bornhövd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001; 45: 736-13.
4. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999; 140: 338-42.
5. Kalthoff FS, Chung J, Stuetz A. Pimecrolimus inhibits up regulation of OX40 and synthesis of inflamatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 2002; 130: 85-92.
6. Nghiem P, Pearsen G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-41.
7. Schopf RE. Pimecrolimus. Novartis. Curr Opin Invest Drugs 2002; 3: 720-4.